<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05030545</url>
  </required_header>
  <id_info>
    <org_study_id>2021P002400</org_study_id>
    <nct_id>NCT05030545</nct_id>
  </id_info>
  <brief_title>Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study</brief_title>
  <official_title>Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study aims to learn more about the impact the hormone aldosterone on the heart.&#xD;
      Primary aldosteronism is a condition where the body's adrenal glands make too much of the&#xD;
      hormone aldosterone, which can cause high blood pressure and increase the risk of heart and&#xD;
      kidney disease. Treatment with medications that block aldosterone can reduce that risk. This&#xD;
      study is trying to learn whether treatment with a medication that blocks aldosterone can&#xD;
      improve heart function in people who make too much aldosterone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study evaluates the impact of 6 months of treatment with the mineralocorticoid receptor&#xD;
      blocking medication eplerenone on the heart's blood flow, using a cardiac PET stress test,&#xD;
      and on the heart's structure and function by echocardiogram.&#xD;
&#xD;
      Participants with a confirmed diagnosis of primary aldosteronism will undergo echocardiogram&#xD;
      and cardiac PET stress test before and after 6 months of eplerenone treatment.&#xD;
&#xD;
      Participants without a confirmed diagnosis of primary aldosteronism but with hypertension and&#xD;
      a recent clinical PET test and echocardiogram will undergo testing to make the diagnosis of&#xD;
      primary aldosteronism. Those who test positive will go on to treatment with eplerenone for 6&#xD;
      months, followed by a cardiac PET scan and echocardiogram.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2026</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in myocardial flow reserve (MFR, unitless ratio)</measure>
    <time_frame>6 months</time_frame>
    <description>The primary outcome is to evaluate the change in MFR, as measured by PET, pre- vs post-6 months of eplerenone therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in peak-stress myocardial blood flow (ml/min/g)</measure>
    <time_frame>6 months</time_frame>
    <description>Peak stress myocardial blood flow is measured by PET after vasodilator-induced maximal hyperemia, before and after 6 months of eplerenone treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Global Longitudinal Strain (%)</measure>
    <time_frame>6 months</time_frame>
    <description>Global Longitudinal Strain is measured by echocardiography before and after 6 months of eplerenone treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LV Mass Index (g/m2 of body surface area)</measure>
    <time_frame>6 months</time_frame>
    <description>LV Mass Index is measured by echocardiography before and after 6 months of eplerenone treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Primary Aldosteronism</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Eplerenone Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eplerenone (50-100mg daily, as tolerated by blood pressure and potassium) for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <description>After baseline cardiac imaging with PET and echocardiogram, participants will be treated with eplerenone for 6 months at a starting dose of 50mg daily and up to a maximally tolerated dose of 100mg daily, followed by repeat imaging with PET and echocardiogram.</description>
    <arm_group_label>Eplerenone Treatment</arm_group_label>
    <other_name>Inspra</other_name>
    <other_name>Mineralocorticoid Receptor Antagonist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Cohort A: Overt &amp; Diagnosed PA&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults aged 18-85&#xD;
&#xD;
          -  Able to provide informed consent and willing to comply with the study&#xD;
&#xD;
          -  Able to fit safely in PET/CT scanner (weight limit 500 pounds; diameter and&#xD;
             circumference of PET/CT scanner are 70 cm and 220 cm, respectively)&#xD;
&#xD;
          -  Hypertension treated with at least one antihypertensive drug&#xD;
&#xD;
          -  Cohort A: Clinically confirmed diagnosis of PA not yet treated with mineralocorticoid&#xD;
             receptor antagonists&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of MI, CABG, known cardiomyopathy (EF &lt;40%, hypertrophic cardiomyopathy,&#xD;
             and/or amyloid), cardiac transplantation&#xD;
&#xD;
          -  Contraindication or allergy to eplerenone or spironolactone&#xD;
&#xD;
          -  Current pregnancy or breastfeeding&#xD;
&#xD;
          -  eGFR &lt; 45 mL/min/1.73m2 or potassium &gt; 5.1 on labs within the preceding 3 months&#xD;
&#xD;
          -  Cohort A: Planned adrenalectomy in the subsequent 6 months&#xD;
&#xD;
        Cohort B: Subclinical &amp; Undiagnosed PA&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults aged 18-85&#xD;
&#xD;
          -  Able to provide informed consent and willing to comply with the study&#xD;
&#xD;
          -  Able to fit safely in PET/CT scanner (weight limit 500 pounds; diameter and&#xD;
             circumference of PET/CT scanner are 70 cm and 220 cm, respectively)&#xD;
&#xD;
          -  Hypertension treated with at least one antihypertensive drug&#xD;
&#xD;
          -  Cohort B: Clinically indicated cardiac PET perfusion scan within the preceding 3&#xD;
             months and echocardiogram within the preceding 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of MI, CABG, known cardiomyopathy (EF &lt;40%, hypertrophic cardiomyopathy,&#xD;
             and/or amyloid), cardiac transplantation&#xD;
&#xD;
          -  Contraindication or allergy to eplerenone or spironolactone&#xD;
&#xD;
          -  Current pregnancy or breastfeeding&#xD;
&#xD;
          -  eGFR &lt; 45 mL/min/1.73m2 or potassium &gt; 5.1 on labs within the preceding 3 months&#xD;
&#xD;
          -  Cohort B: 10% or greater burden of ischemia on qualifying PET&#xD;
&#xD;
          -  Cohort B: Planned coronary angiogram/revascularization in the subsequent 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jenifer M Brown, MD</last_name>
    <phone>6177328052</phone>
    <email>jbrown35@bwh.harvard.edu</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>August 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Jenifer M. Brown, M.D.</investigator_full_name>
    <investigator_title>Instructor in Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperaldosteronism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
    <mesh_term>Mineralocorticoids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

